Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) shares dropped 5.7% during mid-day trading on Thursday . The company traded as low as $4.13 and last traded at $4.16. Approximately 17,449 shares changed hands during mid-day trading, an increase of 706% from the average daily volume of 2,165 shares. The stock had previously closed at $4.41.
Graybug Vision Trading Down 6.1 %
The stock has a fifty day moving average price of $4.44 and a 200-day moving average price of $4.65. The firm has a market capitalization of $6.13 million, a price-to-earnings ratio of -0.17 and a beta of 1.20.
About Graybug Vision
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Stories
- Five stocks we like better than Graybug Vision
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- What is the Australian Securities Exchange (ASX)
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
